Elosulfase Alfa
Brand names: Vimizim · Active ingredient: Elosulfase Alfa
In short: VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
What is Elosulfase Alfa used for?
VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
âš Boxed warning (FDA's strongest warning)
Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.
Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur .
Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions and require additional monitoring .
Elosulfase Alfa dosage
Administration of VIMIZIM should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis .
Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation .
This product must be diluted prior to administration and administered using a low-protein binding infusion set equipped with a low-protein binding 0.2 micrometer (µm) in-line filter.
Consider pre-medicating with antihistamines, with or without antipyretics, 30 to 60 minutes prior to the start of the infusion .
The recommended dosage of VIMIZIM is 2 mg/kg administered intravenously over a minimum range of 3.5 to 4.5 hours (based on infusion volume) once every week.
In the event of a severe hypersensitivity reaction (e.g., anaphylaxis), discontinue the VIMIZIM infusion and immediately initiate appropriate medical treatment, including use of epinephrine. In the event of a mild to moderate hypersensitivity reaction, consider slowing or temporarily interrupting the infusion, or administering additional antihistamines, antipyretics, and/or corticosteroids .
Use aseptic technique during preparation.
Determine the number of VIMIZIM vials based on the patient's actual body weight in kg and the recommended dose .
Remove vials from the refrigerator.
Select the appropriate size 0.9% Sodium Chloride Injection, USP infusion bag and calculate the infusion volume based on patient's actual body weight:
For patients who weigh less than 25 kg, the final infusion volume should be 100 mL
For patients who weigh 25 kg or more, the final infusion volume should be 250 mL.
Withdraw and discard a volume of 0.9% Sodium Chloride Injection, USP from either the 100 mL or 250 mL infusion bag equal to the volume of VIMIZIM to be added.
Withdraw the required volume of VIMIZIM from the vial(s) and add to the 0.9% Sodium Chloride Injection, USP infusion bag. Gently rotate the infusion bag to mix the diluted solution. Avoid vigorous shaking or agitation. Discard unused portion remaining in the vial(s).
Visually inspect the solution for particulate matter and discoloration. The solution should be clear to slightly opalescent and colorless to pale yellow. The diluted VIMIZIM solution may contain proteinaceous particles in the form of translucent fibers which will be removed by the in-line filter during infusion. Discard if opaque particles are present or the solution is discolored.
Use an infusion set equipped with a low-protein binding 0.2 micrometer (µm) in-line filter to administer VIMIZIM.
Do not infuse with other products in the infusion tubing. Compatibility with other products has not been evaluated. …
How to take Elosulfase Alfa — instructions & advice from the label
Hypersensitivity Reactions Including Anaphylaxis
Advise the patient or caregiver that life-threatening hypersensitivity reactions, including anaphylaxis may occur with VIMIZIM treatment.
Advise the patient or caregiver that anaphylaxis has occurred during the early course of enzyme replacement therapy and after 1extended duration of therapy.
Inform the patient or caregiver of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis, and to seek immediate medical care should symptoms occur. The risks and benefits of re-administering VIMIZIM following a severe reaction should be considered .
Warnings & precautions
Do not take this medicine if: None.
Life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with enzyme replacement therapies, including VIMIZIM. In premarketing clinical trials, 18 of 235 (7.7%) patients treated with VIMIZIM experienced signs and symptoms consistent with anaphylaxis. These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria. These cases of anaphylaxis occurred as early as 30 minutes from the start of infusion and up to three hours after infusion. Anaphylaxis occurred as late into treatment as the 47th infusion.
In clinical trials with VIMIZIM, 44 of 235 (18.7%) patients experienced hypersensitivity reactions, including anaphylaxis. Hypersensitivity reactions have occurred as early as 30 minutes from the start of infusion but as late as six days after infusion. Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.
Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Administration of VIMIZIM should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis. Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. …
Elosulfase Alfa side effects
The following serious adverse reactions are described below and elsewhere in the labeling:
Hypersensitivity Reactions Including Anaphylaxis .
Risk of Acute Respiratory Complications .
Spinal or Cervical Cord Compression .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A 24-week, randomized, double-blind, placebo-controlled clinical trial of VIMIZIM was conducted in 176 patients with MPS IVA, ages 5 to 57 years old. Approximately half of the patients (49%) were male. Of the 176 patients, 65% were White, 23% Asian, 3% Black, and 10% Other race. The majority of patients (78%) were non-Hispanic. Patients were randomized to three treatment groups: VIMIZIM 2 mg/kg once per week (n=58), VIMIZIM 2 mg/kg once every other week (n=59), or placebo (n=59). All patients were treated with antihistamines prior to each infusion.
Table 3 summarizes the most common adverse reactions that occurred in the placebo-controlled trial with an incidence of ≥ 10% in patients treated with VIMIZIM 2 mg/kg once per week and with a higher incidence than in the placebo-treated patients. …
About this medicine
Elosulfase alfa is a purified human enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. Human N-acetylgalactosamine-6-sulfatase (EC 3.1.6.4) is a hydrolytic lysosomal glycosaminoglycan-specific enzyme that hydrolyzes sulfate from either galactose-6-sulfate or N-acetyl-galactosamine-6-sulfate on the non-reducing ends of the glycosaminoglycans keratan sulfate (KS) and chondroitin-6-sulfate (C6S).
Elosulfase alfa is a soluble glycosylated dimeric protein with two oligosaccharide chains per monomer. Each monomeric peptide chain contains 496 amino acids and has an approximate molecular mass of 55 kDa (59 kDa including the oligosaccharides). One of the oligosaccharide chains contains bis-mannose-6-phosphate (bisM6P). bisM6P binds a receptor at the cell surface and the binding mediates cellular uptake of the protein to the lysosome. Elosulfase alfa has a specific activity of 2.6 to 6.0 units/mg. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0caa2565-12b2-0ad0-1f9a-273e81c3d4cc. Read the full official label on DailyMed.